References:
  1. Bishop JR. Pharmacogenetics.Handb Clin Neurol. 147:59-73 (2018).
  2. Nebert DW. Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clinical Genetics. 56: 247-258 (1999).
  3. European Medicine Agency. Position paper on terminology in pharmacogenetics discussion at the pharmacogenetics expert group. Eur Med Agency - Comm Propr Med Prod [Internet]. (November):0–6. (2001) Available from: http://www.emea.eu.int. Accessed on 28 May 2020.
  4. Jain KK. Personalized medicine. Curr Opin Mol Ther. 4(6):548–58 (2002).
  5. Mirsadeghi S, Larijani B. Personalized Medicine: Pharmacogenomics and Drug Development.Acta Med Iran . 55(3):150‐165 (2017).
  6. Meyer UA. Drugs in special patient groups: clinical importance of genomics in drug effects. In: Carruthers GS, Hoffmann BB, Melmon KL, Nierenberg DW, eds. New York: McGrawHill, 1179–205 (2000).
  7. Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med 250(3):186‐200 (2001).
  8. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286: 487–91 (1999).
  9. Roses AD. Pharmacogenetics and future drug development and delivery. Lancet 355: 1358–61 (2000).
  10. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116(3):496‐526 (2007).
  11. Food and Drug Administration. Table of pharmacogenomic biomarkers in drug labels [Internet] Springfield, MD: The Administration; Jun 6 2013 [cited 5 May 2020]. https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling Accessed on 28 May 2020.
  12. Shoshi A, Müller U, Shoshi A, Ogultarhan V, Hofestädt R. KALIS - An eHealth System for Biomedical Risk Analysis of Drugs. Stud Health Technol Inform. 236:128-135 (2017).
  13. Weinshilboum RM, Wang L. Pharmacogenomics: Precision Medicine and Drug Response. Mayo Clin Proc. 92(11):1711‐1722 (2017).
  14. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy.Annu Rev Med . 57:119‐137 (2006).
  15. Shepherd G, Mohorn P, Yacoub K, May DW. Adverse drug reaction deaths reported in United States vital statistics, 1999-2006. Ann Pharmacother . 46(2):169‐175 (2012).
  16. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ (Clinical research ed.) 329(7456), 15–19 (2004).
  17. Guideline on summary of product characteristics (SmPC). European commission enterprise and industry directorate-general. European Commission. https://ec.europa.eu/health/ sites/health/files/files/eudralex/vol-2/c/smpc_guideline_rev2_en.pdf. (2009). Accessed 5 May 2020.
  18. Ehmann F, Caneva L, Prasad K, et al. Pharmacogenomic information in drug labels: European Medicines Agency perspective. Pharmacogenomics J. 15(3):201-10. doi: 10.1038/tpj.2014.86 (2015).
  19. Frueh FW, Amur S, Mummaneni P, et al. Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration: prevalence of related drug use. Pharmacotherapy. 28(8):992–998 (2008).
  20. The SmPC of the drugs approved by TDMDA, https://www.titck.gov.tr/kubkt. Accessed on 14 April 2020.
  21. RX Media Pharma Interactive Pharmaceuticals Information Source https://www.eczanet.com/. Accessed on 14 April 2020.
  22. PharmGKB Drug label annotations. https://www.pharmgkb.org/labelAnnotations. Accessed on 14 April 2020.
  23. Haga SB, Mills R, Moaddeb J. Pharmacogenetic information for patients on drug labels.Pharmgenomics Pers Med. 7:297-305 (2014).
  24. Pai SA, Kshirsagar N. A Critical Evaluation of Pharmacogenetic Information in Package Inserts for Selected Drugs Marketed in India and Its Comparison With US FDA-Approved Package Inserts. J Clin Pharmacol. 56(10):1232-42 (2016).
  25. Reis-Pardal J, Rodrigues A, Rodrigues E, Fernandez-Llimos F. Comparing cytochrome P450 pharmacogenetic information available on United States drug labels and European Union Summaries of Product Characteristics.Pharmacogenomics J. 17(6):488-493 (2017).
  26. Schuck RN, Grillo JA. Pharmacogenomic Biomarkers: an FDA Perspective on Utilization in Biological Product Labeling. AAPS J.18(3):573-7 (2016).
  27. Zhu Q, Freimuth RR, Pathak J, Durski MJ, Chute CG. Disambiguation of PharmGKB drug-disease relations with NDF-RT and SPL. J Biomed Inform. 46(4):690-6 (2013).
  28. Preskorn SH, Hatt CR. How pharmacogenomics (PG) are changing practice: implications for prescribers, their patients, and the healthcare system (PG series part I). J Psychiatr Pract. 19(2):142-9 (2013).
  29. Haga SB, Thummel KE, Burke W. Adding pharmacogenetics information to drug labels: lessons learned.Pharmacogenet Genomics. 16(12):847-54 (2006).
  30. Shekhani R, Steinacher L, Swen JJ, Ingelman-Sundberg M. Evaluation of Current Regulation and Guidelines of Pharmacogenomic Drug Labels: Opportunities for Improvements. Clin Pharmacol Ther. 107(5):1240-1255 (2019).
  31. Tan-Koi WC, Leow PC, Teo YY. Applications of pharmacogenomics in regulatory science: a product life cycle review. Pharmacogenomics J. 18(3):359-366 (2018).
  32. Beauchamp TL, Childress JF. Principles of biomedical ethics. 5th ed. New York Oxford University Press; 57-103 (2001).
  33. Brezis M, Israel S, Weinstein-Birenshtock A et al. Quality of informed consent for invasive procedures. Int J Qual Health Care . 20(5):352-357 (2008).
  34. Kureshi F, Jones PG, Buchanan DM, Abdallah MS, Spertus JA. Variation in patients’ perceptions of elective percutaneous coronary intervention in stable coronary artery disease: cross sectional study. BMJ 349: g5309 (2014).
  35. Rose D, Russo J, Wykes T. Taking part in a pharmacogenomic clinical trial: assessment of trial participants understanding of information disclosed during the informed consent process. BMC Med Ethics. 14:34 (2013).
  36. Madadi P. Ethical Perspectives on Translational Pharmacogenetic Research Involving Children.Pediatr Drugs 17:91–95 (2015).
  37. Zakinova A, Long-Boyle JR, French D, et al. A Practical First Step Using Needs Assessment and a Survey Approach to Implementing a Clinical Pharmacogenomics Consult Service. J Am Coll Clin Pharm. 2(3):214‐221 (2019).
  38. Elewa H, Alkhiyami D, Alsahan D, Abdel-Aziz A. A survey on the awareness and attitude of pharmacists and doctors towards the application of pharmacogenomics and its challenges in Qatar. J Eval Clin Pract. 21(4):703‐709 (2015).
  39. Amara N, Blouin-Bougie J, Bouthillier D, Simard J. On the readiness of physicians for pharmacogenomics testing: an empirical assessment.Pharmacogenomics J. 18(2):308‐318 (2018).
  40. Chua EW, Kennedy MA. Current state and future prospects of direct-to-consumer pharmacogenetics.Front. Pharmacol. 3:152 (2012).